ReviewDrugs2013
Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease.Biomedicines · 2024Review
- Cutaneous leukocytoclastic vasculitis induced by continuous erythropoietin receptor activator.JAAD case reports · 2021Article
- Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study.Journal of community hospital internal medicine perspectives · 2021Article
- Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice.Acta diabetologica · 2020Article
- Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients.Canadian journal of kidney health and disease · 2020Article
- Anemia in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Review
- Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.International urology and nephrology · 2015Review
- Erythropoiesis-stimulating agents for anaemia in chronic kidney disease: Are they all the same?The Cochrane database of systematic reviews · 2014Article
- Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.Advances in therapy · 2014Observational
- High dose EPO--friend or foe in the newborn?The Journal of physiology · 2014Article
- Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.Canadian journal of kidney health and disease · 2014Article
- Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Biologics : targets & therapy · 2014Review
- Cost-effectiveness of continuous erythropoietin receptor activator in anemia.ClinicoEconomics and outcomes research : CEOR · 2014Review
- Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.Advances in therapy · 2013Article
- Physiology and pharmacology of erythropoietin.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2013Review
- Anaemia management and mortality risk in chronic kidney disease.Nature reviews. Nephrology · 2013Review
- Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.Drug, healthcare and patient safety · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoiesis-stimulating agents (ESAs) have become a hallmark of anaemia therapy in patients with chronic kidney disease (CKD). Although different ESAs are available for the treatment of renal anaemia, each nephrologist should select a single ESA for an individual patient. Epoetin alfa and epoetin beta have been used 1-3 times weekly but extended-interval dosing up to every 4 weeks is also effective in a substantial majority of CKD patients. However, the epoetin dose necessary to achieve or maintain target haemoglobin (Hb) levels increases substantially as the dosing interval increases. Subcutaneous administration of short-acting ESAs is more effective than the intravenous route of administration. Darbepoetin alfa and the continuous erythropoietin receptor activator (CERA) have been developed as a treatment for anaemia with extended administration intervals (every 2 weeks and every 4 weeks, respectively). Dose requirements for these long-acting ESAs are independent of the route of administration. Patents of short-acting ESAs have expired, which has opened the field for biosimilars. Epoetin biosimilars approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) have been shown to have a comparable efficacy and safety profile to their originators. An alarming increase in pure red cell aplasia (PRCA) in Thailand with follow-on epoetins manufactured in Asia (but also those manufactured in Latin America) indicates that stringent country-specific approval and pharmacovigilance protocols for ESAs manufactured in non-North American and non-EU European countries are urgently needed. Two PRCA cases occurring with subcutaneous HX575 (one certain, one likely) indicate that chances of inducing a more immunogenic product are unpredictable, even with a biosimilar epoetin approved under the EMA biosimilar approval pathway. Phase III clinical trials with peginesatide, a pegylated synthetic peptide-based ESA without any homology to erythropoietin raised safety concerns in non-dialysis CKD patients but not in dialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.